Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation - The New England Journal of Medicine - 2019

Brief Summary:

Among patients with AF presenting with ACS or undergoing PCI, apixaban is associated with a 4.2% absolute reduction in major or clinically relevant nonmajor bleeding when compared to warfarin at 180 days. Apixaban was also associated with a 3.9% absolute reduction in death or hospitalization when compared to warfarin (driven primarily by reduced hospitalization). Aspirin use in addition to oral anticoagulation and P2Y12 inhibitor therapy was associated with a 7.1% absolute increase in major or clinically relevant nonmajor bleeding. Overall thrombotic events were similar across individuals randomized to anticoagulation with apixaban versus warfarin, and those randomized to aspirin versus placebo.